FDA fast-tracks Shire's SHP655 for patients with ADAMTS13
Shire PLC's recombinant ADAMTS13 drug, SHP655, has been given fast-track designation by the U.S. Food and Drug Administration. Read More »
CVS Health to bring Pharmacists Teach program to Pittsburgh public schools
CVS Health recently announced a partnership with the University of Pittsburgh School of Pharmacy and the Pittsburgh Public Schools that will showcase the company’s Pharmacists Teach prescription drug prevention program to public school students with the help of student pharmacists from the university. Read More »
Auryxia by Keryx has been picked up by nation's largest Medicare Part D sponsor
Keryx Pharmaceuticals Inc.'s largest Medicare Part D plan sponsor in the United States has added the company’s Auryxia drug to its Medicare Part D plan formularies. Read More »
Bavencio treatment for Merkel cell carcinoma patients gains FDA approval
EMD Serano, the biopharmaceutical business of Merck KGaA, and Pfizer Inc. recently received approval from the U.S. Food and Drug Administration to market Bavencio Injection 20 mg/mL for intravenous use. Read More »
Phase 3 trials for sarecycline meet primary endpoints
Allergan PLC and Parateks Pharmaceuticals' Phase 3 trials of sarecycline met their 12-week primary efficacy endpoints. Read More »
FDA approves Symproic once-daily tablets to treat OIC
Shionogi Inc. and Purdue Pharma L.P.'s Symproic 0.2 mg tablets C-II have been approved by the U.S. Food and Drug Administration for use as a once-daily oral peripherally-acting mu-opioid receptor antagonist medication in treating opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain. Read More »
Rituxan receives breakthrough status from FDA
Genentech's drug Rituxan was recently granted Breakthrough Therapy Designation Status by the U.S. Food and Drug Administration. Read More »
Cumberland's multicenter study supports Vaprisol Injection
Cumberland Pharmaceuticals Inc.'s open label multicenter study, published in Drug Design, Development and Therapy, supports the efficacy and use of Vaprisol Injection for treating hyponatremic patients with severe hepatic impairment. Read More »
European Commission approves XELJANZ for rheumatoid arthritis
XELJANZ (tofacitinib citrate) has been approved by the European Commission in mono or combination therapy for rheumatoid arthritis. Read More »
Walgreens designates 50 pharmacies as cancer care centers
Walgreens recently designated over 50 of its nationwide pharmacy locations as cancer specialty centers outfitted with highly trained staff in breast, prostate, colorectal, lung and blood cancer directives with specialized curricula. Read More »
Pfizer's TRUMENBA moves closer to European approval
Pfizer Inc.'s meningococcal group B vaccine TRUMENBA has received a positive opinion from the European Medicines Agency Committee for Medicinal Products for Human Use. Read More »
AbbVie joins ORIEN Avatar Research Program
AbbVie has joined three other pharmaceutical companies in the Oncology Research Information Exchange Network Avatar Research Program. Read More »
Tildrakizumab filing with European agency validated
The regulatory filing of investigational IL-23p19 inhibitor tildrakizumab with the European Medicines Agency was validated last week, according to Almirall and Sun Pharmaceutical Industries. Read More »
Pharmacy industry report says price discounts miss mark
A group representing pharmacy benefit managers is criticizing a report by a drug industry lobbying group that concludes the managers are not passing along drug rebates and discounts to patients. Read More »
Merck KGaA teams with Avillion for psoriasis treatment
Merck KGaA has signed an agreement with U.K.-based research and development firm Avillion for an investigative, branded pharmaceutical product designed to address plaque psoriasis, with Avillion’s financial support. Read More »
Alerts Sign-up